Vitamin E prevents extensive lipid peroxidation in patients with hypertension

British Journal of Biomedical Science

Volumn 60, Issue 1, 2003, Pages 5-8

  Brockes, Christiane ^a   Buchli, C ^a   Locher, R ^a   Koch, J ^a   Vetter, W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Hypertension; Vitamin E

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; COPPER ION; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; LIPID PEROXIDATION; LIPID STORAGE; MALE; PHOTOMETRY; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

ANIMALIA;

EID: 0037238136     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2003.11783669     Document Type: Article

References (38)

1. Kannel WB, Sorlie P. Hypertension in Framingham. In: Paul O, ed. Epidemiology and control of hypertension. New York: Stratton International Medical Book Cooperation, 1975: 553-92.
2. Allemann Y, Weidmann P Cardiovascular, metabolic and hormonal dysregulation in normotensive offspring of essential hypertensive parents. J Hypertens 1995; 13: 163-73.
3. Pierdomenico SD, Constantini F, Bucci A, De Cesare D, Cuccurullo F, Mezzetti A. Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension 1998; 31: 621-6.
4. Bracht C, Locher R, Suter P, Vetter W. LDL-Oxidation bei essentieller Hypertonie. Kardiovaskuläre Medizin 1997; 1: 54-8.
5. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density liproproteins that increases its atherogenicity. N Engl J Med 1989; 320: 1196-7.
7. Grundy SM. Oxidized LDL and atherogenesis: relation to risk factors for coronary heart disease. Clin Cardiol 1993; 16:(4 Suppl 1): I3-5.
8. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
9. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143-52.
10. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
11. Devaraj S, Jialal I. The effects of alpha-tocopherol on critical cells in atherogenesis. Curr Opin Lipidol 1998; 9: 11-5.
12. Odeh RM, Cornich LA. Natural antioxidants for the prevention of atherosclerosis. Pharmacotherapy 1995; 15: 647-59.
13. Kinlay S, Fang JC, Hikita H et al. Plasma alpha-tocopherol and coronary endothelium-dependent vasodilator function. Circulation 1999; 100: 219-21.
14. Swain RA, Kaplan Machlis B. Therapeutic uses of vitamin E in prevention of atherosclerosis. Altern Med Rev 1999; 4: 414-23.
15. Austin MA, Breslow JL, Hennekens CH, Buring, JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21.
16. Odeh RM, Cornish LA. Natural antioxidants for the prevention of atherosclerosis. Pharmacotherapy 1995; 15: 648-59.
17. Pryor WA. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic Biol Med 2000; 28: 141-64.
18. Pezeshk A, Derick Dalhouse A. Vitamin E, membrane fluidity and blood pressure in hypertensive and normotensive rats. Life Sci 2000; 1: 1881-9.
19. Keaney JF, Simon DI, Freedman JE. Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB J 1999; 13: 965-75.
20. Mottram P, Shige H, Nestel P. Vitamin E improves arterial compliance in middle-aged men and women. Atheroselerosis 1999; 145: 399-404.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
22. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Contiuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Rad Res Commun 1989; 67-75.
23. Pyörälä K. Interpopulation correlations between serum cholesterol level and the occurrence of coronary heart disease. Eur Heart J 1987, 8: 23-30.
24. O'Leary VJ, Tilling L, Fleetwood G, Stone D, Darley-Usmar V. The resistance of low-density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy. Athersclerosis 1996; 119: 169-79.
25. Digiesi V, Oliviero C, Gianno V et al. Reactive metabolites of oxygen, lipid peroxidation, total antioxidant capacity and vitamin E in essential hypertension. Clin Ter 1997; 148: 515-9.
26. Maggi E, Marchesi R, Ravetta V, Falaschi F, Finardi G, Bellomo G. Low-density lipoprotein oxidation in essential hypertension. J Hypertens 1993; 11: 1103-11.
27. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.
28. Shimano H, Yamada N, Ishibashi S et al. Oxidation-labile subfraction of human plasma low-density lipoprotein isolated by ion-exchange chromatography. J Lipid Res 1991; 32: 763-73.
29. Jun-Jun W, Xiao-Zhuan L, Yi-Yi Z, Lu-Yan L. Correlation between susceptibility of LDL subfractions to in vitro oxidation and in vivo oxidised LDL. Clin Biochem 2000; 3: 71-3.
30. Vasankari T, Ahotuba M, Toikka J et al. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men with lower levels of oxidized LDL with statin therapy. Atherosclerosis 2001; 155: 403-12.
31. Lengfelder W. Antioxidative vitamin: Prävention von kardiovaskulären Erkrankungen. Dtsch Med Wschr 1998; 123: 1014-7.
32. Steinberg D. Clinical trial of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995; 346: 36-8.
33. Bunout D. Therapeutic potential of vitamin E in heart disease. Expert Opin Investig Drugs 2000; 9: 2629-35.
34. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 2001; 73: 673-86.
35. Mosca L, Rubenfire M, Mandel C et al. Antioxidant nutrient supplementation reduces the susceptibility of low-density lipoprotein to oxidation in patients with coronary artery disease. J Am Coll Cardiol 1997; 30: 392-9.
36. Rimm EB, Stampfer MJ. Antioxidants for vascular disease. Med Clin North Am 2000; 84: 239-49.
37. Croft KD, Dimmitt SB, Moulton C, Beilin LJ. Low-density lipoprotein composition and oxidizability in coronary artery disease apparent favourable effect of beta-blockers. Athersclerosis 1992; 97: 123-30.
38. Lupo E, Locher R, de Graaf J, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxdition compared with alpha-tocopherol. Biochem Biophys Res Commun 1994; 203: 1803-8.